**Adalimumab**, sold under the brand name **Humira**, among others, is a [monoclonal antibody](https://en.wikipedia.org/wiki/Monoclonal_antibody "Monoclonal antibody") used to treat [rheumatoid arthritis](https://en.wikipedia.org/wiki/Rheumatoid_arthritis "Rheumatoid arthritis"), [psoriatic arthritis](https://en.wikipedia.org/wiki/Psoriatic_arthritis "Psoriatic arthritis"), [ankylosing spondylitis](https://en.wikipedia.org/wiki/Ankylosing_spondylitis "Ankylosing spondylitis"), [[Crohn's Disease]], [[Ulcerative Colitis|Ulcerative Colitis]], [plaque psoriasis](https://en.wikipedia.org/wiki/Plaque_psoriasis "Plaque psoriasis"), [hidradenitis suppurativa](https://en.wikipedia.org/wiki/Hidradenitis_suppurativa "Hidradenitis suppurativa"), [uveitis](https://en.wikipedia.org/wiki/Uveitis "Uveitis"), and [juvenile idiopathic arthritis](https://en.wikipedia.org/wiki/Juvenile_idiopathic_arthritis "Juvenile idiopathic arthritis"). It is administered by [injection under the skin](https://en.wikipedia.org/wiki/Subcutaneous_injection "Subcutaneous injection")